Mackenzie Financial’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $84.7M | Buy |
135,783
+49,466
| +57% | +$33.7M | 0.08% | 192 |
|
|
2026
Q1 | $66.7M | Buy |
86,317
+7,581
| +10% | +$5.8M | 0.08% | 205 |
|
|
2025
Q4 | $60.8M | Sell |
78,736
-49,887
| -39% | -$33.9M | 0.07% | 225 |
|
|
2025
Q3 | $72.3M | Buy |
128,623
+27,205
| +27% | +$15.4M | 0.09% | 198 |
|
|
2025
Q2 | $53.2M | Buy |
101,418
+34,458
| +51% | +$19.2M | 0.07% | 220 |
|
|
2025
Q1 | $42.5M | Buy |
66,960
+11,928
| +22% | +$8.2M | 0.06% | 236 |
|
|
2024
Q4 | $39.2M | Sell |
55,032
-960
| -2% | -$806K | 0.05% | 246 |
|
|
2024
Q3 | $58.9M | Sell |
55,992
-1,972
| -3% | -$2.19M | 0.08% | 206 |
|
|
2024
Q2 | $60.9M | Buy |
57,964
+2,074
| +4% | +$2.01M | 0.09% | 184 |
|
|
2024
Q1 | $53.8M | Sell |
55,890
-395
| -0.7% | -$376K | 0.08% | 210 |
|
|
2023
Q4 | $49.4M | Sell |
56,285
-61
| -0.1% | -$50.2K | 0.07% | 213 |
|
|
2023
Q3 | $45.5M | Sell |
56,346
-3,298
| -6% | -$2.59M | 0.08% | 206 |
|
|
2023
Q2 | $42.8M | Sell |
59,644
-7,066
| -11% | -$5.45M | 0.07% | 231 |
|
|
2023
Q1 | $54.8M | Sell |
66,710
-5,239
| -7% | -$3.95M | 0.08% | 209 |
|
|
2022
Q4 | $51.9M | Sell |
71,949
-9,787
| -12% | -$7.22M | 0.09% | 198 |
|
|
2022
Q3 | $56.3M | Sell |
81,736
-7,512
| -8% | -$4.73M | 0.1% | 193 |
|
|
2022
Q2 | $52.8M | Sell |
89,248
-4,662
| -5% | -$3.03M | 0.08% | 204 |
|
|
2022
Q1 | $65.6M | Buy |
93,910
+5,702
| +6% | +$3.61M | 0.09% | 202 |
|
|
2021
Q4 | $55.7M | Sell |
88,208
-362
| -0.4% | -$223K | 0.08% | 229 |
|
|
2021
Q3 | $53.6M | Buy |
88,570
+119
| +0.1% | +$73.9K | 0.08% | 225 |
|
|
2021
Q2 | $49.4M | Buy |
88,451
+18,282
| +26% | +$9.26M | 0.07% | 227 |
|
|
2021
Q1 | $33.2M | Buy |
70,169
+33,297
| +90% | +$16.2M | 0.05% | 258 |
|
|
2020
Q4 | $17.8M | Buy |
36,872
+5,465
| +17% | +$2.95M | 0.04% | 268 |
|
|
2020
Q3 | $17.6M | Buy |
31,407
+8,125
| +35% | +$4.93M | 0.04% | 240 |
|
|
2020
Q2 | $14.5M | Buy |
23,282
+4,521
| +24% | +$2.57M | 0.04% | 260 |
|
|
2020
Q1 | $9.16M | Buy |
18,761
+593
| +3% | +$245K | 0.03% | 285 |
|
|
2019
Q4 | $6.82M | Buy |
18,168
+14,722
| +427% | +$4.95M | 0.02% | 384 |
|
|
2019
Q3 | $956K | Buy |
3,446
+2,485
| +259% | +$735K | ﹤0.01% | 727 |
|
|
2019
Q2 | $301K | Sell |
961
-5,851
| -86% | -$1.95M | ﹤0.01% | 959 |
|
|
2019
Q1 | $2.8M | Buy |
6,812
+5,308
| +353% | +$2.19M | 0.01% | 698 |
|
|
2018
Q4 | $562K | Sell |
1,504
-4
| -0.3% | -$1.46K | ﹤0.01% | 917 |
|
|
2018
Q3 | $609K | Buy |
1,508
+225
| +18% | +$85.6K | ﹤0.01% | 838 |
|
|
2018
Q2 | $443K | Buy |
1,283
+271
| +27% | +$84.8K | ﹤0.01% | 812 |
|
|
2018
Q1 | $348K | Buy |
1,012
+469
| +86% | +$163K | ﹤0.01% | 785 |
|
|
2017
Q4 | $204K | Buy |
+543
| New | +$220K | ﹤0.01% | 797 |
|
Other funds holding REGN
Mackenzie Financial's REGN Position: Q2 2026 in Review
Mackenzie Financial increased its Regeneron Pharmaceuticals (REGN) stake by 57% in Q2 2026, buying an estimated $33.7M and bringing the position to 135,783 shares worth $84.7M. The position accounts for 0.08% of the portfolio, ranked #192.
Mackenzie Financial first reported a position in REGN in Q4 2017 and has held it in 35 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Mackenzie Financial held 135,783 shares of Regeneron Pharmaceuticals worth $84.7M as of Q2 2026.
- Mackenzie Financial bought 49,466 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $33.7M.
- Regeneron Pharmaceuticals made up 0.08% of Mackenzie Financial's portfolio in Q2 2026, its #192 holding.
- Mackenzie Financial first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.